A new clinical trial highlights that spotting a genetic subtype of these ATC tumors can be key to designing treatment that ...

Oncogenic activation usually results from point mutation rather than gene rearrangement. The most common BRAF mutation is the T1796A point mutation, resulting in a glutamic acid (E) to valine (V ...

Gandeeva Therapeutics Inc. has divulged serine/threonine-protein kinase B-raf (BRAF)/MAP2K1 (MEK1) interaction stabilizers reported to be useful for the treatment of brain metastasis.

We played a major role in characterising the BRAF gene and its role in cancer, increasing our understanding of malignant melanoma. Our work on the gene and the structure of the BRAF protein ...

A new clinical trial highlights that spotting a genetic subtype of these ATC tumors can be key to designing treatment that ...

91 percent accuracy for the NTRK1 gene mutation found in head and neck cancers, and 89 percent accuracy for the BRAF gene mutation in thyroid cancer. For the task of predicting patient survival ...

Caris Life Sciences has obtained an FDA approval for its MI Cancer Seek tumor profiling assay, unlocking its use as a ...

BRAF V600E mutations are seen in around 20 different ... The findings reinforce the importance of genetic testing for cancers to enable the use of targeted treatment, according to ROAR's lead ...

Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune ...

A new clinical trial highlights that spotting a genetic subtype of these ATC tumors can be key to designing treatment that greatly extends survival ATC patients with BRAF gene mutations lived a ...